{
    "symbol": "BIO",
    "quarter": 3,
    "year": 2022,
    "date": "2022-10-27 22:23:03",
    "content": " Net sales for the third quarter of 2022 were $680.8 million, which is an 8.9% decline on a reported basis versus $747 million in Q3 of 2021. Year-over-year core revenue, which excludes COVID-related sales and the 10x $32 million settlement in the third quarter of 2021 increased 6.1% on a currency neutral basis. Sales of the Life Science Group in the third quarter of 2022 were $317.9 million compared to $373.5 million in Q3 of 2021, which is a 14.9% decline on a reported basis and an 11% decline on a currency-neutral basis. Sales of the Clinical Diagnostics Group in the third quarter were $361.9 million compared to $372.2 million in Q3 of 2021, which is a 2.8% decline on a reported basis and growth of 3% on a currency-neutral basis."
}